Cryopreservation: an optimizing factor for therapeutic potential of fetoplacental complex products

The therapeutic potential of cryopreserved fetoplacental complex cells (FPCP) has been explored for the treatment of autoimmune diseases, including autoimmune hemolytical anemia (AIHA). In this study, a murine AIHA model was utilized to investigate the application of cryopreserved fetal liver cells (cFLC), from varying gestation intervals (14 and 19 postcoital days) to correct the functional state of the lymphohemopoietic complex (LHPC). The results demonstrate that cryopreservation had little negative effect on FLC-14 corrective ability from that of nonfrozen FLC-14. Cryopreservation of FLC-19 (later gestation period) resulted in an increase in functional corrective potential over that of matched controls. Further, the increase in corrective effect of the cFLC-19 was found to be similar to that of both FLC-14 populations. In summary, these results demonstrate the potential for the use of cryopreserved FLCs as a therapeutic option for the treatment of AIHA.